Macquarie Group Ltd. Has $97.21 Million Holdings in GlaxoSmithKline plc (GSK)

Macquarie Group Ltd. decreased its holdings in GlaxoSmithKline plc (NYSE:GSK) by 2.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,394,363 shares of the pharmaceutical company’s stock after selling 56,930 shares during the quarter. Macquarie Group Ltd. owned 0.10% of GlaxoSmithKline worth $97,211,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its position in GlaxoSmithKline by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares during the period. Fisher Asset Management LLC grew its position in GlaxoSmithKline by 2.3% in the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after acquiring an additional 293,866 shares during the period. Renaissance Technologies LLC grew its position in GlaxoSmithKline by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares during the period. Hotchkis & Wiley Capital Management LLC grew its position in GlaxoSmithKline by 4.3% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after acquiring an additional 322,700 shares during the period. Finally, Federated Investors Inc. PA grew its position in GlaxoSmithKline by 22.7% in the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after acquiring an additional 833,501 shares during the period. 9.83% of the stock is owned by institutional investors and hedge funds.

GlaxoSmithKline plc (NYSE GSK) traded up $0.26 during trading on Friday, reaching $35.32. The company’s stock had a trading volume of 5,393,594 shares, compared to its average volume of 4,411,884. GlaxoSmithKline plc has a one year low of $34.72 and a one year high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The firm has a market capitalization of $86,863.92, a PE ratio of 12.52, a PEG ratio of 1.96 and a beta of 0.98.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a dividend of $0.5037 per share. The ex-dividend date is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.70%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 163.12%.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average price of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.

GSK has been the subject of several analyst reports. UBS upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and raised their price target for the stock from $35.04 to $35.85 in a research report on Monday, November 27th. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Morgan Stanley cut GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. BidaskClub upgraded GlaxoSmithKline from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Finally, Argus reiterated a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline in a research note on Thursday, August 31st. Three analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and an average target price of $39.71.

TRADEMARK VIOLATION NOTICE: This news story was first published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://weekherald.com/2017/12/04/glaxosmithkline-plc-gsk-holdings-lowered-by-macquarie-group-ltd.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply